BRPI0923502A2 - composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho - Google Patents

composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho

Info

Publication number
BRPI0923502A2
BRPI0923502A2 BRPI0923502A BRPI0923502A BRPI0923502A2 BR PI0923502 A2 BRPI0923502 A2 BR PI0923502A2 BR PI0923502 A BRPI0923502 A BR PI0923502A BR PI0923502 A BRPI0923502 A BR PI0923502A BR PI0923502 A2 BRPI0923502 A2 BR PI0923502A2
Authority
BR
Brazil
Prior art keywords
eye
active agent
provide efficient
posterior segment
topical ocular
Prior art date
Application number
BRPI0923502A
Other languages
English (en)
Inventor
Wayne Schneider L
A Chowan Masood
Wehsin Han Wesley
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0923502A2 publication Critical patent/BRPI0923502A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0923502A 2008-12-22 2009-12-08 composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho BRPI0923502A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13970108P 2008-12-22 2008-12-22
PCT/US2009/067159 WO2010074961A1 (en) 2008-12-22 2009-12-08 Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
BRPI0923502A2 true BRPI0923502A2 (pt) 2019-09-24

Family

ID=41559537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923502A BRPI0923502A2 (pt) 2008-12-22 2009-12-08 composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho

Country Status (15)

Country Link
US (1) US20100160342A1 (pt)
EP (1) EP2367528A1 (pt)
JP (1) JP2012513393A (pt)
KR (1) KR20110099044A (pt)
CN (1) CN102264344A (pt)
AR (1) AR074828A1 (pt)
AU (1) AU2009330517A1 (pt)
BR (1) BRPI0923502A2 (pt)
CA (1) CA2747917A1 (pt)
CL (1) CL2009002197A1 (pt)
MX (1) MX2011005586A (pt)
RU (1) RU2011130552A (pt)
TW (1) TW201028176A (pt)
UY (1) UY32353A (pt)
WO (1) WO2010074961A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664905B (zh) * 2013-12-25 2015-10-14 四川科瑞德制药有限公司 盐酸坦度螺酮晶型ii及其制备方法
CN108619100B (zh) * 2017-03-16 2022-05-13 四川科瑞德制药股份有限公司 一种氮杂螺酮类药物注射剂及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US5286719A (en) * 1991-10-28 1994-02-15 Mona Industries, Inc. Phospholipid virucidal compositions
US5648348A (en) * 1991-10-28 1997-07-15 Mona Industries, Inc. Phospholipid antimicrobial compositions
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
DK0877600T3 (da) * 1996-08-09 2004-02-02 Alcon Mfg Ltd Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US20030207890A1 (en) * 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
AR062046A1 (es) * 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
AR066901A1 (es) * 2007-05-18 2009-09-23 Alcon Mfg Ltd Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength

Also Published As

Publication number Publication date
EP2367528A1 (en) 2011-09-28
JP2012513393A (ja) 2012-06-14
US20100160342A1 (en) 2010-06-24
RU2011130552A (ru) 2013-01-27
UY32353A (es) 2010-04-30
AR074828A1 (es) 2011-02-16
CA2747917A1 (en) 2010-07-01
KR20110099044A (ko) 2011-09-05
WO2010074961A1 (en) 2010-07-01
MX2011005586A (es) 2011-06-20
CN102264344A (zh) 2011-11-30
TW201028176A (en) 2010-08-01
CL2009002197A1 (es) 2011-02-11
AU2009330517A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
BRPI0909174A2 (pt) Composição cosméticas para proporcionar peliculas super hidrofóbicas
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
WO2012085523A3 (en) Skin sanitizer compositions comprising alcohol based emulsion
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
BR112013009483A2 (pt) "estrutura substancialmente desprovida de celulose para utilização em um artigo absorvente, artigo absorvente e método de fabricação de uma estrutura abosrvente"
DK2252258T3 (da) Anvendelse af naturlige aktive stoffer i kosmetiske eller terapeutiske sammensætninger
BRPI0912182A2 (pt) distribuição de liberação prolongada de agentes ativos pára tratar glaucoma e hipertensão ocular
BRPI0812954A2 (pt) Composição herbicidamente ativa, método para controlar vegetação indesejada, e, uso de composições
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
IL228758B (en) Masp-2 inhibiting agent for use in treating paroxysmal nocturnal hemoglobinuria
PT3061454T (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014029510A2 (pt) composição esterilizada e meio aquoso compreendendo, pelo menos, um ácido hialurônico e, pelo menos, um sal hidrossolúvel de sacarose octassulfato, processo de fabricação, e de utilização da mesma, formulação cosméstica, e, kit
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
MX2010004613A (es) Composicion topica.
PL2446878T3 (pl) Kompozycje ketorolaku trometaminy stosowane do leczenia lub zapobiegania występowaniu bólu gałki ocznej
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
FR2924024B1 (fr) Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
MX383583B (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
EP2786738A4 (en) HAIR TREATMENT COMPOSITION
MX2013011971A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CR20110660A (es) Mezclas fungicidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.